AC T01546
XX
ID T01546
XX
DT 07.08.1995 (created); ewi.
DT 26.03.2015 (updated); jtr.
CO Copyright (C), QIAGEN.
XX
FA E2F-4
XX
SY E2F transcription factor 4, p107/p130-binding; E2F-4; E2F4.
XX
OS human, Homo sapiens
OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates
XX
GE G002038 E2F4; HGNC: E2F4.
XX
CL C0023; fork head; 3.3.2.1.4.
XX
SF no basic region;
SF homoserine stretch of 16 or 13 residues leading to a discrepancy in size (416 vs. 413 AA) in different references [1] [2];
SF requires heterodimerization with DP-1 or similar proteins for efficient DNA-binding and transcriptional activation [1] [2];
SF prior to crystal structure belongs to bHLH-zip factors [8];
SF specific interaction with p107 [1] [3];
SF can bind to a lesser extent pRb [7];
SF is stably bound to the p130 pocket protein in association with a DP heterodimerization partner in G0 phase [5] [7];
XX
CP fibroblasts [6]; SkBr3, MCF-7, MDA-MB-468, MDA-MB-231, NBE018, NBE234, NBE232B, NBE233 [11].
EX brain,,,adult; detectable; Northern blot; mRNA (poly-A); [1].
EX heart,,,adult; detectable; Northern blot; mRNA (poly-A); [1].
EX kidney (right and left),,,adult; low; Northern blot; mRNA (poly-A); [1].
EX liver,,,adult; detectable; Northern blot; mRNA (poly-A); [1].
EX lung (right and left),,,adult; detectable; Northern blot; mRNA (poly-A); [1].
EX muscles,,,adult; detectable; Northern blot; mRNA (poly-A); [1].
EX pancreas,,,adult; detectable; Northern blot; mRNA (poly-A); [1].
EX placenta,,,adult; detectable; Northern blot; mRNA (poly-A); [1].
XX
FF transcriptional activator, transforming potential [1] [2];
FF constitutively present throughout the cell cycle, but maximally expressed in mid-G1 and before E2F-1 is detectable [7] [4];
FF phosphorylated during cell cycle [1];
FF transcriptional activation repressed by p107-binding [1];
FF p130 -binding effectively suppressed E2F-4-mediated trans-activation [5];
XX
IN T15601 AR; Mammalia.
IN T04074 brca1; human, Homo sapiens.
IN T01548 DP-1; human, Homo sapiens.
IN T01549 DP-1; mouse, Mus musculus.
IN T03000 DP-2; human, Homo sapiens.
IN T04110 HDAC3; human, Homo sapiens.
IN T01486 p107; human, Homo sapiens.
IN T01608 p130; human, Homo sapiens.
IN T06377 PML; human, Homo sapiens.
IN T00722 pRb; human, Homo sapiens.
IN T04689 SMRT; human, Homo sapiens.
XX
MX M04823 V$E2F4_05.
MX M04905 V$E2F4_07.
MX M07084 V$E2F4_09.
MX M07380 V$E2F4_Q3.
MX M02090 V$E2F4_Q6.
MX M00050 V$E2F_02.
MX M00803 V$E2F_Q2.
MX M00918 V$E2F_Q3_01.
MX M00919 V$E2F_Q4_01.
MX M00939 V$E2F_Q4_02.
MX M08875 V$E2F_Q4_03.
MX M00920 V$E2F_Q6_01.
XX
BS R22101.
BS R04555.
BS R25986.
BS R66915.
BS R66924.
BS R66926.
BS R66927.
BS R66928.
BS R30591.
BS R60817.
BS R60142.
BS R08679.
BS R09600.
BS R24728.
BS R61392.
BS R71982.
BS R71983.
BS R71984.
BS R71990.
BS R71977.
BS R30955.
BS R63616.
BS R08847.
BS R39260.
BS R29521.
BS R09599.
BS R25613.
XX
DR TRANSPATH: MO000023603.
DR UniProtKB: Q16254;
XX
RN [1]; RE0003317.
RX PUBMED: 7958924.
RA Ginsberg D., Vairo G., Chittenden T., Xiao Z.-X., Xu G., Wydner K. L., DeCaprio J. A., Lawrence J. B., Livingston D. M.
RT E2F-4, a new member of the E2F transcription factor family, interacts with p107
RL Genes Dev. 8:2665-2679 (1994).
RN [2]; RE0003318.
RX PUBMED: 7958925.
RA Beijersbergen R. L., Kerkhoven R. M., Zhu L., Carlee L., Voorhoeve P. M., Bernards R.
RT E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo
RL Genes Dev. 8:2680-2690 (1994).
RN [3]; RE0003319.
RX PUBMED: 8321204.
RA Chittenden T., Livingston D. M., DeCaprio J. A.
RT Cell cycle analysis of E2F in primary human T cells reveals novel E2F complexes and biochemically distinct forms of free E2F
RL Mol. Cell. Biol. 13:3975-3983 (1993).
RN [4]; RE0003546.
RX PUBMED: 7892279.
RA Sardet C., Vidal M., Cobrinik D., Geng Y., Onufryk C., Chen A., Weinberg R. A.
RT E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle
RL Proc. Natl. Acad. Sci. USA 92:2403-2407 (1995).
RN [5]; RE0010381.
RX PUBMED: 7705662.
RA Vairo G., Livingston D. M., Ginsberg D.
RT Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth supression by different retinoblastoma protein family members
RL Genes Dev. 9:869-881 (1995).
RN [6]; RE0011851.
RX PUBMED: 8524257.
RA Tommasi S., Pfeifer G. P.
RT In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression
RL Mol. Cell. Biol. 15:6901-6913 (1995).
RN [7]; RE0012605.
RX PUBMED: 8657117.
RA Moberg K., Starz M. A., Lees J. A.
RT E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry
RL Mol. Cell. Biol. 16:1436-1449 (1996).
RN [8]; RE0015322.
RX PUBMED: 10090723.
RA Zheng N., Fraenkel E., Pabo C. O., Pavletich N. P.
RT Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP
RL Genes Dev. 13:666-674 (1999).
RN [9]; RE0015951.
RX PUBMED: 10983977.
RA Rempel R. E., Saenz-Robles M. T., Storms R., Morham S., Ishida S., Engel A., Jakoi L., Melhem M. F., Pipas J. M., Smith C., Nevins J. R.
RT Loss of E2F4 activity leads to abnormal development of multiple cellular lineages.
RL Mol. Cell 6:293-306 (2000).
RN [10]; RE0048082.
RX PUBMED: 9244350.
RA Wang H., Shao N., Ding Q. M., Cui J., Reddy E. S., Rao V. N.
RT BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
RL Oncogene 15:143-157 (1997).
RN [11]; RE0053388.
RX PUBMED: 16158053.
RA Lu Z., Luo R. Z., Peng H., Huang M., Nishmoto A., Hunt K. K., Helin K., Liao W. S., Yu Y.
RT E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
RL Oncogene 25:230-239 (2006).
RN [12]; RE0055135.
RX PUBMED: 18542057.
RA Araki K., Kawauchi K., Tanaka N.
RT IKK/NF-kappaB signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for E2F transcription factors.
RL Oncogene 27:5696-5705 (2008).
XX
//